

For the listening benefit of webinar attendees, we have muted all lines and will be starting our presentation shortly.

- This helps prevent background noise (e.g., unmuted phones or phones put on hold) during the webinar.
- This also means we are unable to hear you during the webinar.
- Please submit your questions directly through the webinar platform only.

How to submit questions:

- Open the Q&A feature at the bottom of your screen, type your question related to today's training webinar and hit "enter."
- Once your question is answered, it will appear in the "Answered" tab.
- All questions will be answered by the end of the webinar.

March 2025

Quality Blue -Condition Assessment Program

Evolving incentives for Medicare Advantage



Blue adVantage (HMO) | Blue adVantage (PPO)

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross Blue Shield Association.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).


Affinity Health Group is an independent company that administers health assessments for Blue Cross and Blue Shield of Louisiana.

Y0132_25662PVLA_C



Best Practices in Medical Record Documentation

- Documentation needs to be sufficient to support and substantiate coding for claims or encounter data.
- Chronic conditions need to be reported every calendar year including key condition statuses (e.g., leg amputation and/or transplant status must be reported each year).
- Include condition specificity where required to explain severity of illness, stage or progression (e.g., staging of chronic kidney disease).
- Treatment and reason for level of care needs to be clearly documented; chronic conditions that potentially affect the treatment choices considered should be documented.





Importance of Complete and Accurate Clinical Documentation and ICD-10 Coding

- Providers treating sicker populations have higher average cost and utilization per patient. Risk-adjusted reporting can accurately reflect these sicker patients.
- The Centers for Medicare and Medicaid Services (CMS) sets risk scores for a calendar year based on diagnoses from the previous calendar year.
- All existing diagnoses must be submitted every calendar year for risk scores to be accurate.
- Member attribution is done by wellness exams.

Importance of Primary Care Providers

The PCP should:

- Develop and grow the provider-member relationship while being proactive and cost effective.
- Oversee, coordinate, discuss and direct the member's care with the member's care team, specialists and hospital staff.
- Assist in coordinating the member's medically necessary services.

When a member changes PCPs, upon request, the prior PCP has 10 business days of the request to submit records to new PCP.

Members who have a strong relationship with their PCPs are healthier, more adherent to their medication regimen and less likely to be hospitalized.

*Quality and Experience of Outpatient Care in the United States for Adults With or Without Primary Care: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2721037

*Primary care visits increase utilization of evidence-based preventative health measures: https://bmcprimcare.biomedcentral.com/articles/10.1186/s12875-020-01216-8

Importance of Annual Wellness Visits

- Provides the ability to effectively assess your patients' chronic conditions, as well as close care and coding gaps for Blue Advantage patients.
- Covered at 100%, once every calendar year, for Blue Advantage patients.

<u>Quality</u>

 Assess and capture outstanding Star Rating care gaps for value-based contract performance and better patient outcomes.

Risk Adjustment

 Greater appointment time allotment for comprehensive assessment and care planning for chronic conditions.





Coding for Annual Wellness Visits

G0438: Initial Annual Wellness Visit (AWV)

G0439: Subsequent AWV

G0402: Initial Preventative Physical Examination (IPPE)

G0468: FQHC Encounter for AWV or IPPE

ICD-10: Z00.00 or Z00.01 medical examination with or without abnormal findings and all applicable diagnoses

For telemedicine visits, bill appropriate wellness visit CPT[®] code (Modifier 95 and POS 10).

More information about these codes can be found on CMS.gov at <u>https://www.cms.gov/Outreach-and-Education/Medicare-</u> Learning-Network-MLN/MLNProducts/preventive-services/medicare-wellness-visits.html#IPPEsits

RHC Reporting Requirement – Modifier CG

Rural health clinics (RHCs) shall report Modifier CG (policy criteria applied) on RHC claims and claim adjustments. Providers should report Modifier CG on one line with a medical and/or mental health HCPCS code that represents the primary reason for the medically necessary face-to-face visit. This line should have the bundled charges for all services subject to coinsurance and deductible. If only preventative services are furnished during the visit, report Modifier CG with the preventive service HCPCS code that represents the primary reason for the medically necessary face-to-face visit.

- Medical and preventative services HCPCS codes are billed with revenue code 052X.
- Mental health services HCPCS codes are billed with revenue code 0900.

Claims submitted without Modifier CG will process incorrectly and the provider will need to adjust the claim.

For additional details, please review the following:

- Rural Health Clinics Reporting Requirements Frequently Asked Questions
- Rural Health Clinic Qualifying Visit List (RHC QVL)

Quality Blue - Condition Assessment Program

Evolving incentives for Medicare Advantage



Wellness Coupon Program

- Used by Vantage since 2015 & Louisiana Blue since 2020
- Educated on proper billing MA Annual Wellness Visits
- Alerted PCPs to suspect diagnoses
- Incentivized completion of visits

Patient Name:	Primary Care Provider (PCP):	
Patient Address:	PCP Signature:	
	NPI#:	
D0B:	Date of Visit:	
Member ID #:		

PROBLEM LIST - Please select ALL that apply to this patient and KEEP A COPY OF THIS IN THE CHART. Vantage pays an additional 520 to the provider when this form is completed and faxed to (318) 361-2159. ALSO, REMEMBER TO INCLUDE ALL SELECTED DIAGNOSES ON YOUR WELLINESS VISIT CLAIM TO RECEIVE THE \$20,00, You may be requested to send a corrected claim if diagnoses marked are not billed on the wellness claim. For any questions or concerns, please call Vantage Health Plan at (318) 998-0409.

Bill one of the following as primary:			Status Codes		
Wellness Exam without abnormal findings	(700.00)		Tracheoston		
OR	(E00.00)		Colostomy -	Z93.3	
Wellness Exam with abnormal findings (Z)	10.011		Ileostomy –	Z93.2	
Cardiovascular/Circulatory	00.017		Renal Dialys	is Status - Z99.2	
Abdominal Aortic Aneurysm – 171.4			Non-Compli	ant with renal Dialy	sis - Z91.15
Angina Pectoris – 120.9			Status Amp	utation type:	
Angina Pectors – 120.9		10	Psychological		
Atheroscierosis of coronary artery with un Atrial Fibrillation – 148.0	isp. Angina - 125.1	19	Alcohol Dep	endence - F10.20	
			Substance D	ependence - F19.2	20
Benign Hypertensive Kidney with CKD sta	ge 5 - 112.0		Specify typ	e of substance:	
Choose also CKD stage – N18.5 Heart Failure, unspecified – I50.9			Bipolar Diso	rder - F31.9	
			Schizophren	nia – F20.9	
Peripheral Vascular Disease – 173.9			Major Depres	sive Disorder Recu	rrent
Hypertensive Heart Disease with Heart Fa	ilure I11.0		Mild - F33.0		
Respiratory			Moderate F:	33.1	
Asthma - J45.909			Severe F33.2		
COPD - J44.9			Unspecified		
Cystic Fibrosis – E84.9			Gastrointestin		
Emphysema – J43.9			Celiac Disea		
Neurological			Chronic Her		
Epilepsy – G40.909			Cirrhosis of		
Polyneuropathy, unspecified – G62.9)isease – K86.9	
Late effects CVA Hemiplegia/Paresis – 169.	.959		Ulcerative C		
Parkinson's Disease – G20			Crohn's Dise		
Hematological			L Cronn's Dise	ase - K50.90	
HIV status - Z21			Chronic Kidne	y Disease	
Sickle Cell without crisis – D57.1			Stage	GFR	ICD-10
Sickle Cell Trait – D57.3				>90	N18.1
Endocrine (select ALL that apply)	Type II	Type I	D 2	60-90	N18.2
DM without complications	E11.9	E10.9	03	30-59	N18.3
DM with hyperglycemia (A1C>7)	E11.65	E10.65	0 4	15-29	N18.45
DM with nephropathy	E11.21	E10.21	0 5	<15 or dialysis	N18.5
(2 + urine micro 3 mo. apart)					
DM with CKD	E11.22	E10.22	Other commo		
Choose also CKD stage N18's				e disorder - F17.200	
DM with unspecified DM retinopathy	E11.319	E10.319	Hypertensic		
without macular edema			Hyperlipder		
DM with DM Polyneuropathy	DE11.42	CE10.42	Hypothyroid	dism - E03.9	
DM with DM PVD without gangrene		C E10.51	GERD - K21.	9	
DM with Foot Ulcer		DE10.621	Anxiety - F4	1.9	
Use additional code to ID site and type (L97.4–L97.5)			Insomnia - 0 Please list ar	547.00 Ny current maligna	ncies also.
Long-Term Insulin Use – Z79.4				and site if indicate	
□ Morbid Obesity (BMI > 40) – E66.01					
Choose also: BMI:					
CH0036 8000, 0000.					





Louisiana Blue spent 2024 evaluating the effectiveness of the Wellness Coupon program after frequent provider feedback indicated its limitations.

Limitations of Coupon Program

- Paper Based
- Limited scalability
- Extra work for PCP & Plan to complete & reconcile
- Poor distribution tool for suspect DX

In 2025, the Blue Advantage Wellness Coupon Program will be replaced by the new Quality Blue – Condition Assessment Program.

Coupons for 2024 DOS were accepted through 2/28/2025.



QB – Condition Assessment Program

- AWV Completion Payment of \$60 per completed AWV, available to all network PCPs
- Two options for Condition Assessment:
 - 1. Condition Assessment via Epic Payment of \$40 per condition assessed
 - 2. Condition Assessment via Stellar Health Payment of \$40 per condition assessed
 - Minimum attribution requirements apply to enrollment in Stellar Health



QB – Condition Assessment Program

 Providers who <u>do not</u> participate in condition assessment with Epic or Stellar and have 10+ members are eligible for an escalating Annual Incentive for reaching thresholds of AWV completion.

• Panel AWV Completion Rate:

- Over 50% \$5 PMPY
 Over 60% \$15 PMPY
 Over 80% \$20 PMPY
- o Over 90% \$25 PMPY

Pay for Performance Medicare Advantage Star Rating Incentive



- We are optimizing the reimbursement for PCPs through a Pay for Performance Medicare Advantage Star Incentive (P4P MA SI) module related to outcomes surrounding population health measures.
- Since October 1, 2022, all PCPs participating in our Blue Advantage network(s) are eligible to receive performance incentive payments for the 2022 calendar year and subsequent calendar years based on closing gaps in care for population health measures.
- We are structuring the P4P MA SI like the Blue Advantage Primary Care Provider Pay for Performance (QB BA PCP P4P) module that is part of the Quality Blue (QB) program. For BA PCPs in the QB program, self-contracted or contracted with another QB provider, your QB BA PCP P4P agreement remains the same.
- In prior years, Blue Advantage has evaluated each PCP individually. Effective in 2024, Star Ratings will be evaluated at the QB group or Tax ID Number (TIN) level.



Measures are categorized as Foundational, Enhanced, and High Focus:

Measure	Category	Factor	Steward	
Breast Cancer Screening (BCS)	Foundational	1.0	HEDIS	
Colorectal Cancer Screening (COL)	Foundational	1.0	HEDIS	
Kidney Health Evaluation for Patients with Diabetes (KED)	Foundational	1.0	HEDIS	
Medication Adherence for Diabetes Medications (ADH- Diabetes)	Foundational	1.0	CMS	
Medication Adherence for Hypertension (ADH- RAS Antagonists)	Foundational	1.0	CMS	
Medication Adherence for Cholesterol (ADH- Statins)	Foundational	1.0	CMS	
Eye Exam for Patients with Diabetes (EED)	Enhanced	0.5	CMS	
Hemoglobin A1c for Patients with Diabetes (HBD)	Enhanced	0.5	CMS	
Controlling High Blood Pressure (CBP)	Enhanced	0.5	CMS	
Plan All-Cause Readmissions (PCR)	Enhanced	0.5	CMS	
Statin Therapy for Patients with Cardiovascular Disease (SPC)	High Focus	1.5	HEDIS	
Statin Use for Patients with Diabetes (SUPD)	High Focus	1.5	HEDIS	

- **Foundational:** Measured using claims data. **These measures carry a factor of 1.0**.
- Enhanced: More advanced and may require the exchange of clinical data or medical coding including applicable CPT II codes as defined by measure, in the absence of a data feed. These measures carry a factor of 0.5.
- <u>High Focus:</u> Those where members have a significant need to improve health outcomes. These are medication measures. **These measures carry a factor of 1.5**.



Sample Scorecard - For illustrative purposes only

Category	Num.	Den.	Rate	Star	Weight ⁽¹⁾	Factor	Weight * Factor	Star * Weight * Factor
	Α	В	A/B = C	D	E	F	E*F	D*E*F
Foundational	40	50	80%	5	10	1	10	50
Foundational	70	100	70%	3	10	1	10	30
Foundational	25	30	83%	4	10	1	10	40
Foundational	23	30	76%	4	10	1	10	40
Foundational	29	30	97%	5	10	1	10	50
Foundational	5	7	71%	4	7	1	7	28
Enhanced	61	70	87%	3	10	0.5	5	15
Enhanced	26	30	87%	3	10	0.5	5	15
Enhanced	62	70	86%	3	10	0.5	5	15
Enhanced	6	7	86%	4	7	0.5	3.5	14
High Focus	6	7	86%	4	7	1.5	10.5	42
High Focus	6	7	86%	4	7	1.5	10.5	42
							н	1
							97	381
								3.95
				+	_	+	_	3.35
	Foundational Foundational Foundational Foundational Foundational Foundational Enhanced Enhanced Enhanced High Focus	AFoundational40Foundational70Foundational25Foundational23Foundational29Foundational5Enhanced61Enhanced62Enhanced6High Focus6	ABFoundational4050Foundational70100Foundational2530Foundational2330Foundational2930Foundational57Enhanced6170Enhanced6270Enhanced67High Focus67	A B A/B = C Foundational 40 50 80% Foundational 70 100 70% Foundational 25 30 83% Foundational 23 30 76% Foundational 29 30 97% Foundational 5 7 71% Enhanced 61 70 87% Enhanced 62 70 86% High Focus 6 7 86%	A B A/B = C D Foundational 40 50 80% 5 Foundational 70 100 70% 3 Foundational 25 30 83% 4 Foundational 23 30 76% 4 Foundational 29 30 97% 5 Foundational 5 7 71% 4 Enhanced 61 70 87% 3 Enhanced 62 70 86% 4 High Focus 6 7 86% 4	A B A/B = C D E Foundational 40 50 80% 5 10 Foundational 70 100 70% 3 10 Foundational 25 30 83% 4 10 Foundational 25 30 83% 4 10 Foundational 23 30 76% 4 10 Foundational 29 30 97% 5 10 Foundational 5 7 71% 4 7 Enhanced 61 70 87% 3 10 Enhanced 26 30 87% 3 10 Enhanced 62 70 86% 4 7 High Focus 6 7 86% 4 7 High Focus 6 7 86% 4 7	A B A/B = C D E F Foundational 40 50 80% 5 10 1 Foundational 70 100 70% 3 10 1 Foundational 25 30 83% 4 10 1 Foundational 23 30 76% 4 10 1 Foundational 23 30 97% 5 10 1 Foundational 29 30 97% 5 10 1 Foundational 5 7 71% 4 7 1 Enhanced 61 70 87% 3 10 0.5 Enhanced 62 70 86% 3 10 0.5 Enhanced 6 7 86% 4 7 1.5 High Focus 6 7 86% 4 7 1.5	Category Num. Den. Rate Star Weight ¹⁻⁷ Factor Factor A B A/B = C D E F E*F Foundational 40 50 80% 5 10 1 10 Foundational 70 100 70% 3 10 1 10 Foundational 25 30 83% 4 10 1 10 Foundational 23 30 76% 4 10 1 10 Foundational 29 30 97% 5 10 1 10 Foundational 5 7 71% 4 7 1 7 Enhanced 61 70 87% 3 10 0.5 5 Enhanced 62 70 86% 3 10 0.5 5 Enhanced 6 7 86% 4 7 1.5 10.5

(1) If denominator is over 10, a weight of 10 is applied. Otherwise weight is denominator.

I/H



Retired Measures

- Diabetes Care-Hemoglobin A1C Test
- Care of Older Adults measures
- Osteoporosis
 Management in
 Women who had a
 Fracture

New Measures

- Diabetes Care-Blood Sugar Controlled
- Controlling High Blood Pressure
- Plan All Cause
 Readmissions

CPT II Resources for new Star Measures



Measure	Definition	CPT II Codes
Controlling High Blood Pressure	The percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and	3074F (systolic < 130 mmHg)
	whose BP was adequately controlled (< 140/90 mmHg) during the measurement year.	3075F (systolic = 130-139 mmHg)
		3077F (systolic≥ 140 mmHg)
		3078F (diastolic < 80 mmHg)
		3079F (diastolic = 80-89 mmHg)
		3080F (diastolic ≥ 90 mmHg)
Controlling Blood Sugar	The percentage of members 18-85 years of age with diabetes (types 1 and 2) whose	3044F A1c < 7%
	hemoglobin A1c (HbA1c) was > 9% during the measurement year.	3046F A1c > 9%
		3051F A1c ≥ 7% and < 8%
		3052F A1c ≥ 8% and ≤ 9%

Statin Use in Persons with Diabetes (SUPD)

Measure Description

Percentage of patients with diabetes receiving statin therapy

Calculation (numerator/denominator)

- Numerator: Number of patients in the denominator who received *any* statin medication fill during the current measurement year
- Denominator: Number of patients 40-75 years old with at least two diabetes medication fills, on two separate dates, during the current measurement year

Measure Rationale

- The American Diabetes Association (ADA) Standards of Medical Care in Diabetes recommends the use of a statin regardless of lipid levels in patients 40-75 years of age with diabetes.
- These patients without additional ASCVD risk are recommended to use a moderate-intensity statin.
- Patients with ASCVD and diabetes are recommended to use a high-intensity statin.

Exclusion Criteria and ICD-10-CM Codes

- Hospice
- •ESRD or Dialysis: 112.0, 113.11, 113.2, N18.5, N18.6, N19, Z91.15, Z99.2
- •Myopathy: G72.0, G72.89, G72.9
- •Rhabdomyolysis: M62.82
- Pre-diabetes: R73.03, R73.09
- •Liver Cirrhosis: K70.30, K70.31, K71.7, K74.3, K74.4, K74.5, K74.60, K74.69, P78.81 •PCOS: E28.2
- Pregnancy, lactation, or infertility: Please call Clinical Pharmacy Services toll-free at 1-833-955-3820 (TTY 711) Monday Friday from 8 a.m. to 5 p.m. for qualifying ICD-10 codes.

Statin Therapy for Patients with Cardiovascular Disease (SPC)

Measure Description

 Percentage of patients with clinical atherosclerotic cardiovascular disease (ASCVD) receiving statin therapy

Calculation (numerator/denominator)

- Numerator: Patients that were dispensed at least one *high* or *moderate-intensity* statin during the measurement year
- Denominator: Males 21-75 years of age and females 40-75 years of age during the measurement year identified as having clinical ASCVD

Measure Rationale

- In members that are 75 years or younger with ASCVD, the American College of Cardiology (ACC) and American Heart Association (AHA) 2018 guidelines recommend a high-intensity statin.
- •A moderate-intensity statin is recommended for those who experience statinassociated side effects at a high-intensity dose.

Exclusion Criteria and ICD-10-CM Codes

- Hospice
- •Deceased during the measurement year
- Palliative Care: Z51.5
- •ESRD or dialysis: 112.0, 113.11, 113.2, N18.5, N18.6, N19, Z91.15, Z99.2
- •Myalgia: M79.10–M79.12, M79.18
- Myositis: M60.80, M60.9
- Myopathy: G72.0, G72.89, G72.9
- Rhabdomyolysis: M62.82
- Liver Cirrhosis: K70.30, K70.31, K71.7, K74.3, K74.4, K74.5, K74.60, K74.69, P78.81
- Pregnancy, infertility or dispensed clomiphene prescription: Please call Clinical Pharmacy Services toll-free at 1-833-955-3820 (TTY 711) Monday Friday from 8 a.m. to 5 p.m. for qualifying ICD-10 codes.
- Members 66 years of age and older: Institutional SNP (I-SNP) enrolled, living in a long-term care facility, frailty & advanced illness diagnosis, or a dispensed dementia medication

Best Practices to Help Close the Gap in Care

Evaluate Gaps in Care Information

- Identify patients who meet measure criteria and who do not have a statin fill
- Identify which prescribers have the most opportunities for statin initiation

Recommendations to Encourage Appropriate Statin Therapy

- Build alerts into the EMR to notify providers of patients in need of a statin based on diagnoses
- Develop a protocol to initiate statins in patients who meet the criteria

Prescribing Statins


- Prescribe three-month supplies and remind patient to refill on schedule to encourage better adherence
- Utilize mail order and turn on auto-refills when using Express Scripts Pharmacy

Statin Intolerance

- Studies show that almost half of patients can tolerate the same statin upon rechallenge;
 - Rosuvastatin, pravastatin and fluvastatin are the least likely to have drug interactions
- Consider alternate dosing schedule

Pay for Performance (P4P) Medicare Advantage Star Rating Incentive

4 Star: \$50 PMPY 5 Star: \$100 PMPY Note: Payments are Risk Adjusted



All PCPs participating in our Blue Advantage network(s) are eligible to receive performance incentive payments based on closing gaps in care for CMS HEDIS[®] measures.

Blue Advantage P4P Module Financial Incentive for Quality Blue Providers

- Paid annually to the Quality Blue (QB) Provider (contracted entity).
- Financial incentives are named P4P PMPY.
- Earn incentives by achieving a four or five-Star Rating.
- Further risk adjusted per member based on Hierarchical Condition Category (HCC) risk score.
- P4P PMPY can be reconciled by the QB Provider using the Checks feature in the Blue Advantage Provider Portal.
 - The link to the Provider Portal is available under the "Other Sites" section of iLinkBlue (www.lablue.com/ilinkblue).

Star Report



Your Blue adVantage Incentive Plan Update

Dear :

We are providing an update on your earnings from its incentive plans, which includes a Star Report that offers information that can help you maximize incentive payments.

The Star Report displays your performance on several quality measures that are part of the Pay for Performance Medicare Advantage Stars Incentive module. Your current Star rating is a out of 5 (to receive an incentive payment, you must achieve at least a rating of 4, as provided in the Quality Blue Primary Care Program Manual Exhibit which is attached for reference).

$\star \star \star \star \star$

The Star Report includes a list of your Blue Advantage patients that have care gaps related to Star measures. Please evaluate these opportunities at the next patient visit. Medical chart documentation can be faxed to our Quality Improvement Department at (318) 812-5280. If you have any questions, you may call 1-855-545-9457.

Thank you for your commitment to improving the health of your Blue Advantage patients.

Sincerely,

Network Operations Health Services Division



Hub of services due and other relevant member information

Gaps to 4 Star 0	5 Star	Gaps to 5 Star
0	76 50	
	10.50	0
1	79.00	2
0	79.00	1
0	88.00	0
5	85.00	6
1	91.00	1
1	92.00	1
0	92.00	0
1	89.00	1
1	90.00	1
	0 0 5 1 1 0 1	1 75.00 0 79.00 0 88.00 5 85.00 1 91.00 1 92.00 0 92.00 1 89.00

A grid overview of where the provider stands with each measure



Utilizing Your Star Report

unor	nts listed in gray	are still in need of services.			
ast N	lame	First Name	Date Of Birth	Last Known Phone	Risk Score
DOE		JANE	12/03/1947	(999)999-9999	0.39
	Diagnoses that	at were submitted last year	, but have not beer	n submitted this year.	
	ICD10 Code 070.54	Description Chrnc hpt C wo hpat coma	1		
DOE		JON	09/16/1946	(999)999-9999	0.27
(Needs a High o	or Moderate intensity Statin M	Nedication		
DOE	Needs an Annu	JESSIE Jal Wellness Exam	09/16/1946	(999)999-9999	0.82
	Diagnoses that	at were submitted last year	, but have not beer	n submitted this year.	
	ICD10 Code V85.41	Description BMI 40.0-44.9, adult			
DOE		JON	11/21/1952	(999)999-9999	0.38
Prava	Patient is diabe statin, Lovastati	n) .	ing a statin. (Tier 1	Statins: Atorvastatin, Rosuvas	tatin, Simvastatin,
DOE		or Moderate intensity Statin M JON	0707/1936	(999)999-9999	2.91
DOE	Needs an Annu	JON Jal Wellness Exam	0707/1936		2.91
DOE	Needs an Annu Diagnoses tha	JON Jal Wellness Exam at were submitted last year	0707/1936 , but have not beer	n submitted this year.	2.91
DOE	Needs an Annu	JON Jal Wellness Exam	0707/1936		2.91
DOE	Needs an Annu Diagnoses tha	JON ual Wellness Exam at were submitted last year Description	0707/1936 , but have not beer ICD10 Code	n submitted this year. Description	2.91
DOE	Needs an Annu Diagnoses tha ICD10 Code 454.0 M00.9	JON Lal Wellness Exam at were submitted last year Description Leg varicosity w ulcer Pyogenic arthritis,	0707/1936 , but have not beer <u>ICD10 Code</u> 720.2	n submitted this year. Description	2.91
DOE	Needs an Annu Diagnoses tha ICD10 Code 454.0 M00.9	JON Jal Wellness Exam at were submitted last year <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified	0707/1936 , but have not beer <u>ICD10 Code</u> 720.2	n submitted this year. <u>Description</u> Sacrolliitis NEC	
DOE	Needs an Annu Diagnoses tha ICD10 Code 454.0 M00.9 Alternative drug	JON al Wellness Exam at were submitted last year <u>Description</u> Leg varicosify w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand	0707/1936 , but have not been <u>ICD10 Code</u> 720.2 name medications. <u>Alternative Dr</u>	n submitted this year. <u>Description</u> Sacrolliitis NEC	Drug 3
DOE	Needs an Annu Diagnoses tha ICD10 Code 454.0 M00.9 Alternative drug Brand Name	JON val Wellness Exam at were submitted last year <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, <u>Unspecified</u> gs for patient's current brand <u>Alternative Drug 1</u>	0707/1936 , but have not been <u>ICD10 Code</u> 720.2 name medications. <u>Alternative Dr</u>	n submitted this year. <u>Description</u> Sacrollitis NEC nug 2 <u>Alternative</u>	Drug 3
	Needs an Annu Diagnoses thin I <u>CD10 Code</u> 454.0 M00.9 Alternative drug <u>Brand Name</u> Mybetriq	JON at were submitted last year <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2)	0707/1936 , but have not been <u>ICD10 Code</u> 720.2 name medications. <u>Alternative Dr</u> Tolterodine E 11/05/1938	n submitted this year. <u>Description</u> Sacrollitis NEC rug 2 <u>Alternative</u> ir Caps (Tier 2) Trospium E (999)999-9999	Drug 3 r Caps (Tier 2)
	Needs an Annu Diagnoses thin I <u>CD10 Code</u> 454.0 M00.9 Alternative drug <u>Brand Name</u> Mybetriq	JON at were submitted last year <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON	0707/1936 , but have not been <u>ICD10 Code</u> 720.2 name medications. <u>Alternative Dr</u> Tolterodine E 11/05/1938	n submitted this year. <u>Description</u> Sacrollitis NEC rug 2 <u>Alternative</u> ir Caps (Tier 2) Trospium E (999)999-9999	Drua 3 r Caps (Tier 2) 0.73
	Needs an Annu Diagnoses tha ICD10 Code 454.0 M00.9 Alternative dru; Brand Name Mybetriq Diagnoses tha ICD10 Code F31.4	JON JON Jal Wellness Exam at were submitted last year <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last year <u>Description</u> Bipolar disorder, current	0707/1936 , but have not been <u>ICD10 Code</u> 720.2 name medications. <u>Alternative Dr</u> Tolterodine E 11/05/1938 , but have not been <u>ICD10 Code</u> F33.2	n submitted this year. <u>Description</u> Sacrollitis NEC run 2 <u>Alternative</u> r Caps (Tier 2) Trospium E (999)999-9999 n submitted this year. <u>Description</u> Major depressive disorder,	Drua 3 r Caps (Tier 2) 0.73
	Needs an Annu Diagnoses tha ICD10 Code 454.0 M00.9 Alternative dru; Brand Name Mybetriq Diagnoses tha ICD10 Code F31.4	JON Jal Wellness Exam at were submitted last year <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, <u>Unspecified</u> gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last year <u>Description</u> Bipolar disorder, current episode depressed,	0707/1936 , but have not been <u>ICD10 Code</u> 720.2 name medications. <u>Alternative Dr</u> Tolterodine E 11/05/1938 , but have not been <u>ICD10 Code</u> F33.2	n submitted this year. <u>Description</u> Sacrollitis NEC rug 2 <u>Alternative</u> r Caps (Tier 2) Trospium E (999)999-9999 n submitted this year. <u>Description</u> Major depressive disorder, recurrent severe without	Drug 3 r Caps (Tier 2) 0.73

- Members with services due will appear in grey.
- Members with all services complete will turn white.

Utilizing Your Star Report

- Diagnosis codes should be submitted annually.
- Medications with lower cost formulary options will be listed.

		1000000 000000 000	Dr. Joh	n Doe		
		are still in need of services.				
	Vame	First Name	Date Of Birth		Known Phone	Risk Score
DOE		JANE	12/03/1947	(999)	999-9999	0.39
	Diagnoses that	at were submitted last yea	r, but have not beer	n submitte	d this year.	
	ICD10 Code 070.54	Description				
	070.54	Chrnc hpt C wo hpat com	a			
DOE		JON	09/16/1946	(999)	999-9999	0.27
		Occult Blood Test (FOBT) x		nt calendar	year	
	Needs a High o	or Moderate intensity Statin I				
DOE	No. 4	JESSIE Jal Wellness Exam	09/16/1946	(999)	999-9999	0.82
	Needs an Annu	lai vveimess Exam		54 S. 10 S. 17 M		
	Diagnoses that	at were submitted last yea	r, but have not beer	n submitte	d this year.	
	ICD10 Code	Description				
	V85.41	BMI 40.0-44.9, adult				
DOE		JON	11/21/1952		999-9999	0.38
		Occult Blood Test (FOBT) x			and the formation and the state of	
Drava	Patient is diabe statin, Lovastati	tic. Please consider prescril	bing a statin. (Tier 1	Statins: Ato	rvastatin, Rosuvas	statin, Simvastatin,
Plava		ny or Moderate intensity Statin I	Medication			
DOE		JON	0707/1936	(999)	999-9999	2.91
	Needs an Annu	ual Wellness Exam				
		ual Wellness Exam at were submitted last yea	r, but have not beer	n submitte	d this year.	
			r, but have not beer ICD10 Code	n submitte Descript		
	Diagnoses the ICD10 Code 454.0	at were submitted last yea <u>Description</u> Leg varicosity w ulcer			ion	
	Diagnoses that	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis,	ICD10 Code	Descript	ion	
	Diagnoses the ICD10 Code 454.0	at were submitted last yea <u>Description</u> Leg varicosity w ulcer	ICD10 Code	Descript	ion	
	Diagnoses tha ICD10 Code 454.0 M00.9	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis,	ICD10 Code 720.2	Descript	ion	
	Diagnoses tha ICD10 Code 454.0 M00.9	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified	ICD10 Code 720.2	<u>Descript</u> Sacroiliit	ion	Drug 3
	Diagnoses the ICD10 Code 454.0 M00.9 Alternative drug Brand Name	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u>	ICD10 Code 720.2 name medications. <u>Alternative Dr</u>	<u>Descript</u> Sacroiliit rug 2	ion is NEC <u>Alternative</u>	
	Diagnoses tha ICD10 Code 454.0 M00.9 Alternative drug	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand	ICD10 Code 720.2 name medications. <u>Alternative Dr</u>	<u>Descript</u> Sacroiliit rug 2	ion iis NEC	
DOE	Diagnoses the ICD10 Code 454.0 M00.9 Alternative drug Brand Name	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u>	ICD10 Code 720.2 name medications. <u>Alternative Dr</u>	Descript Sacroillid Tug 2 Tr Caps (Tie	ion is NEC <u>Alternative</u>	
DOE	Diagnoses tha ICD10 Code 454.0 M00.9 Alternative drug Brand Name Mybetriq	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON	I name medications. Alternative Dr Tolterodine E 11/05/1938	Descript Sacroilii 1999) Sacroilii Sacroilii Sacroilii Sacroilii Sacroilii Sacroilii Sacroilii Sacroilii Sacroilii	ion is NEC <u>Atternative</u> r 2) Trospium E 999-9999	r Caps (Tier 2)
DOE	Diagnoses tha <u>ICD10 Code</u> 454.0 M00.9 Alternative drug <u>Brand Name</u> Mybetriq Diagnoses tha	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last yea	ICD10 Code 720.2 Iname medications. <u>Alternative Dr</u> Totterodine E 11/05/1938 r, but have not been	Descript Sacroiliit Tua 2 Tr Caps (Tie (999) a submitte	ion is NEC <u>Alternative</u> or 2) Trospium E 999-9999 d this year.	r Caps (Tier 2)
DOE	Diagnoses tha ICD10 Code 454.0 M00.9 Alternative drug Brand Name Mybetriq	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON	I name medications. Alternative Dr Tolterodine E 11/05/1938	Descript Sacroilii Sacroilii (999) a submitter Descript	ion is NEC <u>Alternative</u> or 2) Trospium E 999-9999 d this year.	r Caps (Tier 2) 0.73
DOE	Diagnoses that ICD10 Code 454.0 M00.9 Alternative dru; Brand Name Mybetriq Diagnoses that ICD10 Code	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last yea <u>Description</u>	ICD10 Code 720.2	Descript Sacroilii Sacroilii r Caps (Tie (999) n submitter <u>Descript</u> Major de	ion is NEC Alternative r 2) Trospium E 999-9999 d this year. ion	r Caps (Tier 2) 0.73
DOE	Diagnoses that ICD10 Code 454.0 M00.9 Alternative dru; Brand Name Mybetriq Diagnoses that ICD10 Code	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last yea <u>Description</u> <u>Bipolar</u> disorder, current	ICD10 Code 720.2	Descript Sacroilii Sacroilii r Caps (Tie (999) n submitter <u>Descript</u> Major de	ion is NEC Atternative r 2) Trospium E 999-9999 d this year. ion pressive disorder,	r Caps (Tier 2) 0.73
DOE	Diagnoses tha <u>ICD10 Code</u> 454.0 M00.9 Alternative drug <u>Brand Name</u> Mybetriq Diagnoses tha <u>ICD10 Code</u> F31.4	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Atternative Drua 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last yea <u>Description</u> Bipolar disorder, current episode depressed,	I name medications. Alternative Dr Totterodine E 11/05/1938 r, but have not beer <u>ICD10 Code</u> F33.2	Descript Sacroilii Sacroilii r Caps (Tie (999) n submitter <u>Descript</u> Major de	ion is NEC Atternative r 2) Trospium E 999-9999 d this year. ion pressive disorder,	r Caps (Tier 2) 0.73
DOE	Diagnoses tha <u>ICD10 Code</u> 454.0 M00.9 Alternative drug <u>Brand Name</u> Mybetriq Diagnoses tha <u>ICD10 Code</u> F31.4 Alternative drug	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last yea <u>Description</u> Bipolar disorder, current episode depressed, gs for patient's current brand	I name medications. Alternative Dr Totterodine E 11/05/1938 r, but have not beer ICD10 Code F33.2	Descript Sacroilif Sacroilif un 2 r Caps (Tie (999) n submitte Major de recurren	ion is NEC Atternative r 2) Trospium E 999-9999 d this year. ion pressive disorder, t severe without	r Caps (Tier 2) 0.73
DOE	Diagnoses tha <u>ICD10 Code</u> 454.0 M00.9 Alternative drug <u>Brand Name</u> Mybetriq Diagnoses tha <u>ICD10 Code</u> F31.4	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Atternative Drua 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last yea <u>Description</u> Bipolar disorder, current episode depressed,	I name medications. Alternative Dr Totterodine E 11/05/1938 r, but have not beer <u>ICD10 Code</u> F33.2	Descript Sacroilif Sacroilif un 2 r Caps (Tie (999) n submitte Major de recurren	ion is NEC Atternative r 2) Trospium E 999-9999 d this year. ion pressive disorder,	r Caps (Tier 2) 0.73
DOE	Diagnoses tha <u>ICD10 Code</u> 454.0 M00.9 Alternative drug <u>Brand Name</u> Mybetriq Diagnoses tha <u>ICD10 Code</u> F31.4 Alternative drug	at were submitted last yea <u>Description</u> Leg varicosity w ulcer Pyogenic arthritis, Unspecified gs for patient's current brand <u>Alternative Drug 1</u> Solifenacin Tabs (Tier 2) JON at were submitted last yea <u>Description</u> Bipolar disorder, current episode depressed, gs for patient's current brand	I name medications. Alternative Dr Totterodine E 11/05/1938 r, but have not beer ICD10 Code F33.2	Descript Sacroilit va 2 (999) n submitter Major de recurren	ion is NEC Atternative r 2) Trospium E 999-9999 d this year. ion pressive disorder, t severe without	r Caps (Tier 2) 0.73

Blue Advantage Portal Training

Our **Provider Relations Representatives** are available to provide Blue Advantage portal training to providers and their staff.

To request training, please send an email to **provider.relations@lablue.com**. Put "Blue Advantage Portal Training" in the subject line.

Please include your:

- Name
- Organization name
- Contact information
- Brief description of the training you are requesting



Contact Us

Blue Advantage Customer Service 1-866-508-7145 customerservice@blueadvantagela.com

Provider Relations

1-800-716-2299, option 4 provider.relations@lablue.com

